Evidence map›Paper›PMID 28954241›Full record

ArticleNeoplasia (New York, N.Y.)2017

Targeting the Cohesive Cluster Phenotype in Chordoma via β1 Integrin Increases Ionizing Radiation Efficacy.

William L Harryman, Jaime M C Gard, Kelvin W Pond, Skyler J Simpson, Lucas H Heppner, Daniel Hernandez-Cortes, Andrew S Little, Jennifer M Eschbacher, Anne E Cress

Open access · goldAbstract read
In one paragraph

Article in Neoplasia (New York, N.Y.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

William L HarrymanUniversity of Arizona Cancer Center, 1515 N. Campbell Ave., Tucson, AZ, 85724.
Jaime M C GardUniversity of Arizona Cancer Center, 1515 N. Campbell Ave., Tucson, AZ, 85724.
Kelvin W PondDepartment of Cellular and Molecular Medicine, The University of Arizona, 1515 N. Campbell Ave., Tucson, AZ, 85724.
Skyler J SimpsonUniversity of Arizona Cancer Center, 1515 N. Campbell Ave., Tucson, AZ, 85724; Medical Student Research Program, The University of Arizona College of Medicine, 1515 N. Campbell Ave., Tucson, AZ, 85724.
Lucas H HeppnerUniversity of Arizona Cancer Center, 1515 N. Campbell Ave., Tucson, AZ, 85724.
Daniel Hernandez-CortesCancer Biology Research Program, The University of Arizona, 1515 N. Campbell Ave., Tucson, AZ, 85724.
Andrew S LittleBarrow Neurological Institute, 350 W. Thomas Rd., Phoenix, AZ, 85013.
Jennifer M EschbacherBarrow Neurological Institute, 350 W. Thomas Rd., Phoenix, AZ, 85013.
Anne E CressUniversity of Arizona Cancer Center, 1515 N. Campbell Ave., Tucson, AZ, 85724; Department of Cellular and Molecular Medicine, The University of Arizona, 1515 N. Campbell Ave., Tucson, AZ, 85724. Electronic address: cress@email.arizona.edu.
University of Arizona · USBarrow Neurological Institute · USUniversity of Arizona Cancer Center

Funding

VITAMIN AP30CA023074 · NCI · UNIVERSITY OF ARIZONA · PI Dan Theodorescu · 1985 to 2026
$110.2M
Integrative Cancer Scholars Training GrantT32CA009213 · NCI · UNIVERSITY OF ARIZONA · PI CAREW, JENNIFER S, CURIEL-LEWANDROWSKI, CLARA · 1985 to 2024
$8.6M
SHORT-TERM TRAINING STUDENTS IN HEALTH PROFESSIONAL SCHOT35HL007479 · NHLBI · UNIVERSITY OF ARIZONA · PI GEOFFREY C GURTNER, JAMES Kuang-Jan LIAO · 1985 to 2026
$4.4M
Human Prostate Cancer Metastasis and Laminin Binding IntegrinsR01CA159406 · NCI · UNIVERSITY OF ARIZONA · PI CRESS, ANNE E · 2011 to 2015
$1.5M
NCI NIH HHS P30 CA023074NCI NIH HHS R01 CA159406NCI NIH HHS T32 CA009213NHLBI NIH HHS T35 HL007479
6 · The paper itself

Abstract

Chordoma is a rare, radiation-resistant, skull-base and spinal tumor with high local recurrence containing mixed cell-adhesion phenotypes. We characterized DNA damage response (DDR) signaling (γH2AX, pKAP1, pATM) and survival response to ionizing radiation (IR) in human chordoma samples (42 resections, 23 patients) to test if blocking cell adhesion sensitizes U-CH1 tumor cells to IR. U-CH1 cells expressed brachyury, YAP, and laminin adhesion receptors (CD49c, CD49f, CD44), and approximately 15% to 20% of U-CH1 cells featured an α6 integrin-dependent (CD49f) cohesive cluster phenotype, which confers therapeutic resistance and aids metastasis. DDR to IR in U-CH1 cells was compared to normal prostate epithelial (PrEC) and tumor cells (DU145). Flow cytometry showed a dose- and time-dependent increase in γH2AX and pKAP1 expression in all cell lines. However, nearly 50% of U-CH1 cells exhibited nonresponsive phenotype to IR (measured by γH2AX and pKAP1) independent of cell cycle status. Immunofluorescence microscopy verified that only 15% of U-CH1 clustered cells were γH2AX or pKAP1 positive (versus 80% of nonclustered cells) 2 hours following 2-Gy IR. Conversely, both tumor cell lines were uniformly defective in pATM response. HYD1, a synthetic ECM ligand, inhibited DDR through an unresolved γH2AX response. β1 integrin-blocking antibody (AIIB2) decreased cell survival 50% itself and approximately doubled the IR-induced cell kill at all IR doses observed at 2 and 4 weeks posttreatment. These results suggest that a heterogeneity of DDR to IR exists within a chordoma population. Blocking integrin function alone and/or as an adjuvant to IR may eradicate chordomas containing the cohesive cluster phenotype.

Indexed as

PhenotypeRadiation, IonizingCell Culture TechniquesCell Line, TumorChordomaHumansIntegrin beta1SacrumSpinal NeoplasmsTreatment OutcomeIntegrin beta1

Identifiers

PMID28954241
PMCPMC5614733
OpenAlexW2760448319

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.